

## Artigo

***In Vitro* Evaluation of Synthetic Flavones Against *Trypanosoma cruzi***

Andrade, J. S.; Abreu, L. G.; Sales-Junior, P. A.; Murta, S. M. F.; Taylor, J. G.\*

Rev. Virtual Quim., 2021, 13 (1), 146-155. Data de publicação na Web: 24 de Novembro de 2020

<http://rvq.sbq.org.br>**Avaliação *In Vitro* de Flavonas Sintéticas contra o *Trypanosoma cruzi***

**Resumo:** A doença de Chagas é uma infecção causada pelo protozoário parasita *Trypanosoma cruzi* e afeta cerca de 8 milhões de pessoas em 21 países da América Latina. O tratamento dessa doença ainda se baseia no uso de benzonidazol ou nifurtimox, que apresentam baixas taxas de cura na fase crônica e frequentemente apresentam muitos efeitos colaterais indesejáveis. Aqui, descrevemos a síntese de flavonas e a avaliação de sua atividade tripanocida. As flavonas foram testadas *in vitro* contra o *T. cruzi* e dentre os 13 compostos testados, 6 destes demonstraram alguma atividade tripanocida modesta *in vitro*. Observaram-se melhorias na atividade anti *T. cruzi* para flavonas portadoras de substituintes nitro ou metóxi. Notavelmente, foram mantidas citotoxicidades muito baixas com grupos metoxila, o que sugere que esse grupo funcional favorece compostos tripanocidas mais seletivos. Além disso, a modificação estrutural na posição 3 do anel diidropirona forneceu a flavona mais ativa, o que sugere que a introdução de diferentes funcionalidades nessa posição poderia gerar novos compostos promissores com propriedades tripanocidas.

**Palavras-chave:** Doença de Chagas; flavonas; *Trypanosoma cruzi*; *in vitro*.

**Abstract**

Chagas disease is caused by infection of the parasite protozoan *Trypanosoma cruzi* and affects about 8 million people in 21 countries in Latin America. Treatment of this disease is still based on the use of benznidazole or nifurtimox, which both present low cure rates in the chronic phase and often have many undesirable side effects. Herein, we describe the synthesis of flavones and evaluation of their trypanocidal activity. The flavones were tested to *in vitro* against *T. cruzi* and amongst the 13 compounds tested, 6 of these demonstrated some modest trypanocidal activity *in vitro*. Enhancements in anti *T. cruzi* activity were noted for flavones bearing either nitro or methoxy substituents. Moreover, very low cytotoxicities were maintained for flavones with methoxy groups which suggests that this functional group favors more selective trypanocidal compounds. Finally, structural modification at position 3 of the dihydropyrone ring provided the most active flavone, which suggests that the introduction of different functionalities at this position could yield promising new compounds with trypanocidal properties.

**Keywords:** Chagas disease; Flavones; *Trypanosoma cruzi*; Trypanocidal.

\* Universidade Federal de Ouro Preto, Chemistry Department, ICEB, Campus Universitário Morro do Cruzeiro, CEP 35400-000, Ouro Preto-MG, Brazil.

 [jason@iceb.ufop.br](mailto:jason@iceb.ufop.br)

DOI: [10.21577/1984-6835.20200136](https://doi.org/10.21577/1984-6835.20200136)

## ***In Vitro* Evaluation of Synthetic Flavones Against *Trypanosoma cruzi***

Josimara Souza Andrade,<sup>a</sup> Leonardo Gomes de Abreu,<sup>a</sup> Policarpo Ademar Sales Junior,<sup>b</sup> Silvane Maria Fonseca Murta,<sup>b</sup> Jason Guy Taylor<sup>a,\*</sup>

<sup>a</sup> Universidade Federal de Ouro Preto, Chemistry Department, ICEB, Campus Universitário Morro do Cruzeiro, CEP 35400-000, Ouro Preto-MG, Brazil.

<sup>b</sup> FIOCRUZ, René Rachou Institute, CEP 30190-002, Belo Horizonte-MG, Brazil.

\*[jason@iceb.ufop.br](mailto:jason@iceb.ufop.br)

*Recebido em 5 de Maio de 2020. Aceito para publicação em 20 de Outubro de 2020.*

### **1. Introduction**

### **2. Results and Discussion**

### **3. Conclusion**

### **4. Experimental Section**

#### **4.1. Characterization data**

#### **4.2. Anti-*Trypanosoma cruzi* activity assay (amastigotes and trypomastigotes)**

#### **4.3. In vitro cytotoxic test of trypanocidal compounds**

## **1. Introduction**

Neglected Tropical Diseases affect people living on low incomes in mainly developing countries, causing economic and health problems in many communities. Chagas disease, also called American trypanosomiasis, is an infectious disease caused by the protozoan parasite *Trypanosoma cruzi* (*T. cruzi*), through direct contact with contaminated feces of triatomine bugs.<sup>1,2</sup> Approximately 6 to 7 million people are infected with Chagas disease worldwide, mostly in Latin America.<sup>3,4,5</sup> Currently, only two medicines are employed for the treatment of Chagas disease: nifurtimox (NFX) or benznidazole (BZ), both of which cause undesirable side effects and present low cure rates in the chronic phase of disease.<sup>6, 7</sup> Given the negative economic and social impact caused by Chagas disease, the search for new drugs

has become increasingly necessary to treat this disease. Flavones isolated from plants have been isolated and tested for their anti *T. cruzi* activity. For example, flavone and 7-methoxyflavone isolated from the leaves of *Conchocarpus heterophyllus*<sup>8</sup> and flavone-C-diglycoside isoswertisin- $\alpha$ -L-rhamnoside isolated from the leaves of *Peperomia obtusifolia* (Piperaceae)<sup>9</sup> were assayed against *T. cruzi* and all displayed weak trypanocidal activity. In comparison, the flavone-C-glycoside, isoorientin isolated from Turkish *Ajuga laxmannii* (Lamiaceae) was significantly more potent against *T. cruzi* *in vitro* (Figure 1).<sup>10</sup>

Generally, flavones exhibit very low toxicity and moderate trypanocidal activity, becoming an interesting template for designing more potent and selective derivatives. In this regard, we have prepared and tested synthetic flavones against *T. cruzi*, evaluated their cytotoxic effect against L929 cells and determined the selectivity index.




Figure 1. Trypanocidal Flavones

## 2. Results and Discussion

The method of choice for the synthesis of a range of structurally diverse flavones is based on a straightforward procedure described by Wheeler in 1952 and involves the dehydrative cyclization of certain 1,3-diaryl diketones.<sup>11</sup> The synthesis of the target flavones began with the esterification of 2-hydroxyacetophenones with substituted benzoyl chlorides to provide the corresponding esters **1** (Scheme 1). The esters undergo a Baker-Venkataraman rearrangement in the presence of KOH to afford 1,3-diketones **2**. The 1,3-diaryl-1,3-propanediones **2** have proven to be versatile building blocks for the synthesis of trypanocidal diazepines,<sup>12</sup> isoxazoles<sup>13</sup> and flavanones.<sup>14</sup> Compounds **2** when isolated by precipitation and filtration, were immediately subjected to a condensation reaction under refluxing acetic acid to provide flavones **3a-k** (Scheme 1).


All data for flavones **3a-k** were in complete accordance with literature values (see experimental section).

When employing 2-hydroxyacetophenone and isophthaloyl chloride in the aforementioned synthetic route, the “diflavone” **3l** (Scheme 2) was prepared following a slightly modified procedure described previously by our group.<sup>15</sup>


Finally, in order to assess how the removal of the olefinic hydrogen would impact the trypanocidal activity, flavone **3d** was brominated at the position 3 of the dihydropyrone ring to afford the corresponding flavone **3m** in good yield (Scheme 3).

Thus, with the target compounds in hand, *in vitro* bioassays using trypomastigote and amastigote forms of Tulahuen strain *T. cruzi* were carried out. Once the final products were purified and fully characterized, we carried out *in vitro* bioassays against trypomastigote and intracellular amastigote of β-galactosidase transfected Tulahuen strain of *T. cruzi*. We have opted for an *in vitro* methodology that simultaneously evaluates trypomastigote forms that are initially present in the blood after entering through the bite wound and intracellular amastigotes forms present in the vertebrate host during the acute and chronic phases of the disease.<sup>16</sup> This approach is in accordance with the guidelines proposed by the Fiocruz Program for Research and Technological Development on Chagas Disease and the Drugs for Neglected Diseases Initiative (DNDi).<sup>17</sup> Benznidazole was used as a positive control against *T. cruzi* and cytotoxicity was determined in mammalian L929 cells (Table 1).


Amongst the 13 compounds tested, only six of these presented measurable trypanocidal activity and none of the flavone derivatives were



**Scheme 1.** Synthetic route for the preparation of flavones: i) pyridine, rt, 1 h; ii) pyridine, KOH, 50°C, 1 h; iii) AcOH, H<sub>2</sub>SO<sub>4</sub>, reflux, 1 h

















**Scheme 2.** Synthesis of Flavone 3I



**Scheme 3.** Synthesis of Flavone 3m

**Table 1.** *In vitro* trypanocidal activity, cytotoxicity and selectivity index of bioactive flavones

Compd No.	Flavone	Trypanocide IC <sub>50</sub> ( $\mu$ M)	Cytotoxicity CC <sub>50</sub> ( $\mu$ M)	SI	Log P	TPSA ( $\text{\AA}^2$ )
3a		Inactive	>300	-	3.74	30.21
3b		Inactive	>300	-	4.19	30.21
3c		383.7	>300	-	3.79	39.45
3d		Inactive	>300	-	4.42	30.21
3e		211.8	>300	-	3.37	57.91
3f		Inactive	>300	-	2.88	43.35
3g		97.2	122.5	1.3	3.67	76.03
3h		Inactive	>300	-	3.90	30.21
3i		312.4	>300	-	5.05	39.45
3j		Inactive	>300	-	5.07	30.21
3k		356.1	>300	-	4.82	39.45
3l		Inactive	>300	-	5.51	60.42
3m		39.0	60.0	1.5	5.15	30.21
Benz		3.8	2381	625	-	-

more active than reference drug benznidazole. As expected, almost all of the flavones presented very low cytotoxicity and their cytotoxicity could not be quantified. Initially, compound **3a** was evaluated for trypanocidal activity and this result used for comparison in order to assess Structure Activity Relationships (SAR). Although the anti *T. cruzi* activity for flavone **3a** had been reported to be 9531  $\mu\text{M}$ ,<sup>8</sup> the present *in vitro* assay was not capable of determining the  $\text{IC}_{50}$  for such a weakly active compound. The same was also true for flavones **3b**, **3d**, **3f**, **3h**, **3j** and **3l**. From these results, we can conclude that the introduction of a methyl group and halogens on the pendant benzenoid ring or substitution of this moiety for a furan were not conducive to increasing trypanocidal activity. In contrast, the inclusion of methoxy substituents did allow for measurable trypanocidal activities to be uncovered. Furthermore, flavones **3c**, **3e**, **3i** and **3k** were essentially non-toxic which suggests that the methoxy group favors more selective trypanocidal compounds. The improvements in anti *T. cruzi* activity provided by methoxy substituents has been highlighted in studies on flavanones and chalcones.<sup>14,18</sup> Furthermore, in the case of tricyclic coumarins, a 7 fold increase anti *T. cruzi* activity was observed with the introduction of methoxy substituents.<sup>19</sup> Although flavone **3g** bearing a nitro group was significantly the most active flavone, unfortunately the cytotoxicity and poor selectivity index render flavone **3g** an undesirable candidate for further *in vivo* studies. Finally, a remarkable improvement in trypanocidal activity was noted for brominated flavone **3m** suggesting that modifications at position 3 of the dihydropyrone ring greatly enhances the trypanocidal properties of flavones. Once again, the cytotoxicity was unfavorable for further investigation *in vivo*; nevertheless, these preliminary results suggest that the modification at this position with other functionalities could yield active and selective trypanocidal compounds.

The potential of compounds **3a-m** as candidates for new drugs was also evaluated by using Lipinski parameters, which considers the physicochemical drug descriptors of the molecular properties for the synthesized compounds as calculated by Molinspiration software. The partition coefficient (LogP: octanol/water partition coefficient) describes the equilibrium distribution between two liquid phases such as octanol and water. The

total polar surface area (TPSA) is a measure of the extent of the molecules exposed polar area. The results show that compounds **3c**, **3e**, **3g**, **3k** satisfy Lipinski's rule of five with no violations.<sup>20</sup> Flavones **3j**, **3i**, **3l** and **3m** violate the rule by presenting lipophilicity (Log P) greater than 5.0, which could cause problems with oral bioavailability. Flavones **3c**, **3e**, **3g**, **3k**, **3i** and **3m** showed TPSA values lower than  $90 \text{ \AA}^2$ , values ranging from 30.21 - 76.03  $\text{ \AA}^2$ , indicating that these compounds would have a good permeability in the plasma cell membrane and across the blood brain barrier.

### 3. Conclusion

In conclusion, flavones **3c**, **3e**, **3g**, **3i**, **3k** and **3m** showed moderate trypanocidal activity but none of the tested flavones were more active than reference compound benznidazole. However, this study showed some important aspects with regard to how structural modifications could favour the development of lead compounds for the treatment of Chagas disease. The results indicated that the presence of the methoxy group is beneficial for anti *T. cruzi* activity since flavones bearing this substituent were moderately active and essentially non-toxic. Moreover, structural modification with a halogen at position 3 of the dihydropyrone ring provided the most active flavone, which suggests that the introduction of different functionalities at this position could yield promising new compounds with trypanocidal properties.

### 4. Experimental Section

All commercial reagents were used as received. Anhydrous solvents were purchased from Sigma Aldrich. Flash column chromatography was performed using silica gel 200-400 Mesh. TLC analyses were performed using silica gel plates, using ultraviolet light (254 nm), phosphomolybdic acid or vanillin solution for visualization. Melting points are uncorrected and were recorded on a Buchi B-540 apparatus. For NMR data, the chemical shifts are reported in  $\delta$  (ppm) referenced to residual solvent protons and  $^{13}\text{C}$  signals in deuterated chloroform. Coupling constants (*J*) are expressed in Hertz (Hz). Infrared spectra were

obtained on a Thermo Scientific Nicolet 380 FT-IR apparatus (600–4000  $\text{cm}^{-1}$ , Nicolet Instrument Corp., Madison, WI, USA) using attenuated total reflection (ATR). High Resolution Mass Spectra were obtained on a Shimadzu HPLC-ESI-IT-TOF. SMILES notations of the flavone derivatives were inputted into an online software and subjected to molecular properties prediction by Molinspiration software (software version v2015.01).

#### 4.1. Characterization data

Flavones were prepared according to literature methods.<sup>11</sup>

**2-phenyl-4H-chromen-4-one (3a):** Product obtained as a white solid in 78%. m.p.: 95–97 °C (Lit.<sup>21</sup> mp. 95 – 96 °C); <sup>1</sup>H-NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  6.83 (s, 1 H), 7.42 (t,  $J = 8.0$  Hz, 1H), 7.50–7.59 (m, 4H), 7.67–7.74 (m, 1H), 7.91–7.95 (m, 2H), 8.21 (dd,  $J = 1.7$  Hz, 8.0 Hz, 1H); <sup>13</sup>C-NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  107.5, 118.1, 123.9, 125.2, 125.7, 126.3, 129.1, 131.6, 131.7, 133.8, 156.3, 163.4, 178.52; HRMS (ESI-TOF)  $m/z$  [M + H] Calculated for  $\text{C}_{15}\text{H}_{11}\text{O}_2^+$ : 223.0754. Found: 223.0749.

**2-(*p*-tolyl)-4H-chromen-4-one (3b):** Product obtained as a white solid in 76%. m.p.: 109–110 °C (Lit.<sup>22</sup> mp. 110 – 112 °C); <sup>1</sup>H-NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  2.43 (s, 3H),  $\delta$  6.87 (s, 1H), 7.31 (d,  $J = 8.0$  Hz, 2H), 7.42 (t,  $J = 8.0$  Hz, 1H), 7.55 (d,  $J = 8.0$  Hz, 1H), 7.67–7.72 (m, 1H), 7.81 (d,  $J = 8.3$  Hz, 2H), 8.21 (dd,  $J = 1.5$  Hz, 8.0 Hz, 1H); <sup>13</sup>C-NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  21.5, 106.8, 118.0, 123.8, 125.1, 125.6, 126.2, 128.8, 129.7, 133.7, 142.3, 156.2, 163.6, 178.45; HRMS (ESI-TOF)  $m/z$  [M + H] Calculated for  $\text{C}_{16}\text{H}_{13}\text{O}_2^+$ : 237.2775. Found: 237.1779.

**2-(4-methoxyphenyl)-4H-chromen-4-one (3c):** Product obtained as a white solid in 81%. m.p.: 156–157 °C (Lit.<sup>23</sup> mp. 157 – 159 °C); <sup>1</sup>H-NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.90 (s, 3H), 6.75 (s, 1H), 7.02 (d,  $J = 8.9$  Hz, 2H), 7.40 (t,  $J = 7.3$  Hz, 1H), 7.54 (d,  $J = 8.3$  Hz, 1H), 7.67–7.69 (m, 1H), 7.88 (d,  $J = 8.9$  Hz, 2H), 8.23 (dd,  $J = 1.4$  Hz, 7.9 Hz, 1H); <sup>13</sup>C-NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  55.5, 106.2, 114.5, 117.9, 123.9, 124.0, 125.1, 125.6, 127.9, 133.6, 156.2, 162.4, 163.4, 178.3; HRMS (ESI-TOF)  $m/z$  [M + H] Calculated for  $\text{C}_{16}\text{H}_{13}\text{O}_3^+$ : 253.0859. Found: 253.0851.

**2-(4-chlorophenyl)-4H-chromen-4-one (3d):** Product obtained as a white solid in 69%. m.p.: 186–187 °C (Lit.<sup>24</sup> mp. 187 – 188 °C); <sup>1</sup>H-NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  6.78 (s, 1H), 7.38 – 7.56 (m, 4H)

7.69–7.72 (m, 1H), 7.83 (d,  $J = 8.7$  Hz, 2H), 8.19 (dd,  $J = 1.6$  Hz, 7.9 Hz, 1H); <sup>13</sup>C-NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  107.6, 118.0, 123.8, 125.4, 125.7, 127.5, 129.3, 130.2, 133.9, 137.9, 156.2, 162.2, 178.2; HRMS (ESI-TOF)  $m/z$  [M + H] Calculated for  $\text{C}_{15}\text{H}_{10}\text{ClO}_2^+$ : 257.0364. Found: 257.0371.

**2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one (3e):** Product obtained as a white solid in 58%. m.p.: 172–174 °C (Lit.<sup>25</sup> mp. 172 – 174 °C); <sup>1</sup>H-NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.92 (s, 3H), 3.95 (s, 6H), 6.78 (s, 1H), 7.12 (s, 2H), 7.42 (t,  $J = 7.7$  Hz, 1H), 7.56 (d,  $J = 8.4$  Hz, 1H), 7.70 (t,  $J = 8.2$  Hz, 1H), 8.20 (d,  $J = 7.9$  Hz, 1H); <sup>13</sup>C-NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  56.3, 61.0, 103.6, 107.3, 118.1, 123.8, 125.3, 125.6, 126.9, 133.8, 141.1, 153.5, 156.2, 163.3, 178.4; HRMS (ESI-TOF)  $m/z$  [M + H] Calculated for  $\text{C}_{18}\text{H}_{17}\text{O}_5^+$ : 313.1071. Found: 313.1073.

**2-(furan-2-yl)-4H-chromen-4-one (3f):** Product obtained as a white solid in 64%. m.p.: 130–131 °C (Lit.<sup>26</sup> mp. 134 – 135 °C); <sup>1</sup>H-NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  6.59 – 7.71 (m, 1H), 6.75 (s, 1H), 7.13 (d,  $J = 3.4$  Hz, 1H), 7.39 (t,  $J = 7.8$  Hz, 1H), 7.47 (d,  $J = 8.2$  Hz, 1H), 7.62 – 7.70 (m, 2H), 8.20 (dd,  $J = 1.4$  Hz, 7.9 Hz, 1H); <sup>13</sup>C-NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  105.3, 112.6, 113.4, 117.8, 124.0, 125.2, 125.7, 133.8, 145.9, 146.3, 155.3, 155.7, 177.8; HRMS (ESI-TOF)  $m/z$  [M + H] Calculated for  $\text{C}_{13}\text{H}_9\text{O}_3^+$ : 213.0546. Found: 213.0553.

**2-(3-nitrophenyl)-4H-chromen-4-one (3g):** Product obtained as a white solid in 53%. m.p.: 195–196 °C (Lit.<sup>27</sup> mp. 196 – 197 °C); <sup>1</sup>H-NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  6.90 (s, 1H), 7.46 (t,  $J = 8$  Hz, 1H), 7.62 (d,  $J = 8.3$  Hz, 1H), 7.72 – 7.78 (m, 2H), 8.21 (dd,  $J = 1.5$  Hz, 8.0 Hz, 2H), 8.38 (dd,  $J = 2$  Hz, 8.2 Hz, 1H), 8.80 (t,  $J = 2$  Hz, 1H); <sup>13</sup>C-NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  108.8, 118.2, 121.2, 123.8, 125.7, 125.8, 125.9, 130.3, 131.8, 133.6, 134.3, 148.7, 156.1, 160.5; HRMS (ESI-TOF)  $m/z$  [M + H] Calculated for  $\text{C}_{15}\text{H}_{10}\text{NO}_4^+$ : 268.0604. Found: 268.0601.

**2-(4-fluorophenyl)-4H-chromen-4-one (3h):** Product obtained as a white solid in 71%. m.p.: 147–148 °C (Lit.<sup>28</sup> mp. 145 – 148 °C); <sup>1</sup>H-NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  6.77 (s, 1H), 7.18 – 7.26 (m, 2H), 7.42 (t,  $J = 7.8$  Hz, 1H), 7.54 (d,  $J = 8.4$  Hz, 1H), 7.69 – 7.72 (m, 1H), 7.90 – 7.95 (m, 2H), 8.20 (dd,  $J = 1.5$  Hz, 8.0 Hz, 1H); <sup>13</sup>C-NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  108.8, 118.2 (C-F, d,  $J = 22.9$  Hz), 121.2, 123.8, 125.7, 125.8, 125.9 (C-F, d,  $J = 3.1$  Hz), 130.3, (C-F, d,  $J = 8.8$  Hz), 131.8, 133.6, 134.3, 148.7, 156.1, 160.5 (C-F, d,  $J = 250.6$  Hz), 178.0; HRMS (ESI-TOF)  $m/z$  [M + H] Calculated for  $\text{C}_{15}\text{H}_{10}\text{FO}_2^+$ : 241.0659. Found: 241.0665.

**6,8-dichloro-2-(4-methoxyphenyl)-4H-chromen-4-one (3i):** Product obtained as a white solid in 59%. m.p.: 183–185 °C (Lit.<sup>29</sup> mp. 182 – 184 °C); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 3.92 (s, 3H), 6.78 (s, 1H), 7.05 (d, *J* = 8.0 Hz, 2H), 7.73 (d, *J* = 4.0 Hz, 1H), 7.94 (d, *J* = 8.0 Hz, 2H), 8.10 (d, *J* = 4 Hz, 1 H); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): δ 55.6, 105.7, 114.7, 123.1, 123.8, 124.3, 125.7, 128.2, 130.7, 133.5, 150.4, 162.9, 163.5, 176.3; HRMS (ESI-TOF) *m/z* [M + H] Calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>O<sub>3</sub><sup>+</sup>: 321.0080. Found: 321.0084.

**6-chloro-2-(4-chlorophenyl)-4H-chromen-4-one (3j):** Product obtained as a white solid in 63%. m.p.: 226–227 °C (Lit.<sup>23</sup> mp. 226 – 227 °C); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 6.83 (s, 1H), 7.53 – 7.57 (m, 3H), 7.67 (dd, *J* = 2.6 Hz, 8.9 Hz, 1H), 7.87 (d, *J* = 8.7 Hz, 2H), 8.82 (d, *J* = 2,6 Hz, 1H); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): δ 107.6, 119.8, 124.9, 125.2, 127.6, 129.5, 129.8, 131.4, 134.1, 138.2, 154.5, 162.5, 177.0; HRMS (ESI-TOF) *m/z* [M + H] Calculated for C<sub>15</sub>H<sub>9</sub>Cl<sub>2</sub>O<sub>2</sub><sup>+</sup>: 290.9974. Found: 290.9969.

**6-chloro-2-(4-methoxyphenyl)-7-methyl-4H-chromen-4-one (3k):** Product obtained as a white solid in 60%. m.p.: 225–227 °C (Lit.<sup>30</sup> mp. 227 – 227 °C); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 2.54 (s, 3H), 3.92 (s, 3H), 6.74 (s, 1H), 7.04 (d, *J* = 8.9 Hz, 2H), 7.47 (s, 1H), 7.87 (d, *J* = 8.9 Hz, 2H), 8.19 (s, 1 H); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): δ 20.9, 55.5, 105.9, 114.5, 119.8, 123.0, 123.8, 125.4, 128.0, 131.7, 142.7, 154.4, 162.5, 163.5, 177.2; HRMS (ESI-TOF) *m/z* [M + H] Calculated for C<sub>17</sub>H<sub>14</sub>ClO<sub>3</sub><sup>+</sup>: 301.0626. Found: 301.0619.

**2,2'-(1,3-phenylene)bis(4H-chromen-4-one) (3l):** Product obtained as a white solid in 74%. m.p.: 248–250 °C (Lit.<sup>31</sup> mp. 249 – 250 °C); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 6.98 (s, 2H), 7.50 (t, *J* = 8.0 Hz, 2H), 7.67 (d, *J* = 8.4 Hz, 1H), 7.73 – 7.81 (m, 4H), 8.11 (dd, *J* = 2 Hz, 8.0 Hz, 2H), 8.28 (dd, *J* = 2Hz, 8.0 Hz, 2H), 8,54 (m, 1H); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): δ 108.3, 118.2, 123.9 124.0, 125.6, 125.8, 129.1, 129.9, 132.9, 134.2, 156.3, 162.2, 178.4; HRMS (ESI-TOF) *m/z* [M + H] Calculated for C<sub>24</sub>H<sub>15</sub>O<sub>4</sub><sup>+</sup>: 367.0965. Found: 367.0970.

Flavone **3d** was converted to flavone **3m** following the method described by Bird and co-workers [32]. 3-bromo-2-(4-chlorophenyl)-4H-chromen-4-one (**3m**): Product obtained as a white solid in 62%. m.p.: 175–176 °C (Lit.[22] mp. 178 – 179 °C); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ 7.46 – 7.52 (m, 4H), 7.70 – 7.74 (m, 1H),

7.80 – 7.83 (m, 2H), 8.26 (dd, *J* = 1.6Hz, 8.0Hz, 1H); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): δ 109.4, 117.8, 121.7 125.9, 126.5, 128.7, 130.7, 131.2, 134.3, 137.4, 155.5, 160.8, 172.9; HRMS (ESI-TOF) *m/z* [M + H] Calculated for C<sub>15</sub>H<sub>9</sub>BrClO<sub>2</sub><sup>+</sup>: 334.9496. Found: 334.9489.

#### 4.2. Anti-*Trypanosoma cruzi* activity assay (amastigotes and trypomastigotes)

The *in vitro* anti-*T. cruzi* activity was evaluated on L929 cells (mouse fibroblasts) infected with Tulahuen strain of the parasite expressing the *Escherichia coli* β-galactosidase as reporter gene. Briefly, for the bioassay, 4,000 L929 cells were added to each well of a 96-well microtiter plate. After an overnight incubation, 40,000 trypomastigotes were added to the cells and incubated for 2 h. Then the medium containing extracellular parasites was replaced with 200 μl of fresh medium and the plate was incubated for an additional 48 h to establish the infection. For IC<sub>50</sub> determination, the cells were exposed to each synthesized compound at serial decreasing dilutions and the plate was incubated for 96 h. After this period, 50 μl of 500 μM chlorophenol red beta-D-galactopyranoside (CPRG) in 0.5% Nonidet P40 was added to each well, and the plate was incubated for 16 to 20 h, after which the absorbance at 570 nm was measured. Controls with uninfected cells, untreated infected cells, infected cells treated with benznidazole at 3.8 μM (positive control) or DMSO 1% were used. The results were expressed as the percentage of *T. cruzi* growth inhibition in compound-tested cells as compared to the infected cells and untreated cells. The IC<sub>50</sub> values were calculated by linear interpolation. Quadruplicates were run in the same plate, and the experiments were repeated at least once.

#### 4.3. *In vitro* cytotoxic test of trypanocidal compounds

The active compounds were tested *in vitro* for determination of cellular toxicity against uninfected L-929 cells using the alamarBlue® dye. The cells were exposed to compounds at increasing concentrations starting at IC<sub>50</sub> value for *T. cruzi*. After 96 h of incubation with the tested compounds, the alamarBlue® was added and the absorbance at 570 and 600 nm measured



after 4-6 h. The cell viability was expressed as the percentage of difference in the reduction between treated and untreated cells. Quadruplicates were run in the same plate, and the experiments were repeated at least once.  $CC_{50}$  values were calculated by linear interpolation and the selectivity index (SI) was determined based on the ratio of the  $CC_{50}$  value in the host cell divided by the  $IC_{50}$  value of the parasite.

## Acknowledgements

This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. Authors gratefully acknowledge the generous financial support from the Universidade Federal de Ouro Preto (UFOP), FAPEMIG and the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The authors thank the Program for Technological Development of Tools for Health-PDTIS-FIOCRUZ for use of its facilities (Chagas disease platform Pla-Bio Tc). The authors thank the Laboratório Multiusuário de Caracterização de Moléculas (UFOP) for Nuclear Magnetic Resonance service. The authors would also like to thank Prof. Dr. Robson Jose de Cassia Afonso (UFOP) and Ananda Lima Sanson (UFOP) for the excellent mass spectrometry service. Policarpo Ademar Sales Junior is research fellow supported by Programa de Pós-graduação em Ciências da Saúde, Fiocruz Minas (CAPES/PNPD).

## References

- Argolo, A. M.; Felix, M.; Pacheco, R.; Costa, J. *A Doença de Chagas e seus Principais Vetores no Brasil*. SciELO Books: Rio de Janeiro, **2008**. [CrossRef]
- Coura, J. R.; de Castro, S. L. A Critical Review on Chagas Disease Chemotherapy. *Memórias do Instituto Oswaldo Cruz* **2002**, *97*, 3. [CrossRef] [PubMed]
- World Health Organization (WHO). Investing to overcome the global impact of neglected tropical diseases **2015**, *3*, 93. [link]
- World Health Organization (WHO), Chagas disease. Available in: <[http://www.who.int/news-room/fact-sheets/detail/chagas-disease-\(american-trypanosomiasis\)](http://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis))> Accessed in: 5<sup>th</sup> July 2017.
- Schmunis, G. A. Epidemiology of Chagas disease in non endemic countries: the role of international migration. *Memórias do Instituto Oswaldo Cruz* **2007**, *102*, 75. [CrossRef] [PubMed]
- Oliveira, F. M.; Nagao-Dias, A. T.; de Pontes, V. M. O.; de Souza Júnior, A. S.; Coelho, H. L. L.; Coelho, I. C. B. Etiologic treatment of Chagas disease in Brazil. *Revista de Patologia Tropical* **2008**, *37*, 209. [CrossRef]
- Sales Junior, P. A.; Molina, I.; Murta, S. M. F.; Sánchez-Montalvá, A.; Salvador, F.; Corrêa-Oliveira, R.; Carneiro, C. M. Experimental and Clinical Treatment of Chagas Disease: A Review. *The American Journal of Tropical Medicine and Hygiene* **2017**, *97*, 1289. [CrossRef]
- Ambrozini, A. R. P.; Vieira, P. C.; Fernandes, J. B.; da Silva, M. F. G. F.; de Albuquerque, S. Trypanocidal activity of Meliaceae and Rutaceae plant extracts. *Memórias do Instituto Oswaldo Cruz* **2004**, *99*, 227. [CrossRef]
- Mota, J. S.; Leite, A. C.; Batista Junior, J. M.; Lopez, S. N.; Ambrosio, D. L.; Passerini, G. D.; Kato, M. J.; Bolzani, V. S.; Cicarelli, R. M. B.; Furlan, M. *In vitro* trypanocidal activity of phenolic derivatives from *Peperomia obtusifolia*. *Planta medica* **2009**, *75*, 620. [CrossRef] [PubMed]
- Atay, I.; Kirmizibekmez, H.; Kaiser, M.; Akaydin, G.; Yesilada, E.; Tasdemir, D. Evaluation of *in vitro* antiprotozoal activity of *Ajuga laxmannii* and its secondary metabolites. *Pharmaceutical biology* **2016**, *54*, 1808. [CrossRef] [PubMed]
- Wheeler, T. S.; Flavone. *Organic Syntheses* **1952**, *32*, 72. [CrossRef]
- Menezes, J. C. L.; Vaz, L. B. A.; Vieira, P. M. A.; Fonseca, K. S.; Carneiro, C. M.; Taylor, J. G. Synthesis and Anti-*Trypanosoma cruzi* Activity of Diaryldiazepines. *Molecules* **2015**, *20*, 43. [CrossRef] [PubMed]
- De Souza, A. A. N.; Xavier, V. F.; Coelho, G. S.; Sales Junior, P. A.; Romanha, A. J.; Murta, S. M. F.; Carneiro, C. M.; Taylor, J. G. Synthesis of 3,5-Diarylisoazole Derivatives and Evaluation of *in vitro* Trypanocidal Activity. *Journal of Brazilian Chemical Society* **2018**, *29*, 269. [CrossRef]
- Diogo, G. M.; Andrade, J. S.; Sales Júnior, P. A.; Murta, S. M. F.; Dos Santos, V. M. R.; Taylor, J. G. Trypanocidal Activity of Flavanone Derivatives. *Molecules* **2020**, *25*, 397. [CrossRef] [PubMed]
- De Brito, A. C. F.; Correa, R. S.; Pinto, A. A.; Matos, M. J. S.; Tenorio, J. C.; Taylor, J. G.; Cazati, T. Synthesis, crystal structure, photophysical properties and theoretical studies of a novel bis (phenylisoxazolyl) benzene derivative. *Journal of Molecular Structure* **2018**, *1163*, 197. [CrossRef]

- <sup>16</sup> Elias, P. R.; Coelho, G. S.; Xavier, V. F.; Sales Junior, P. A.; Romanha, A. J.; Murta, S. M. F.; Carneiro, C. M.; Camilo, N. S.; Hilário, F. F.; Taylor, J. G. Synthesis of Xylitan Derivatives and Preliminary Evaluation of *in Vitro* Trypanocidal Activity. *Molecules* **2016**, *21*, 1342. [CrossRef] [PubMed]
- <sup>17</sup> Romanha, A. J.; de Castro, S. L. Soeiro, M. N. C.; Lannes-Vieira, J.; Ribeiro, I.; Talvani, A.; Bourdin, B.; Blum, B.; Olivieri, B.; Zani, C.; Spadafora, C.; Chiari, E.; Chatelain, E.; Chaves, G.; Calzada, J. E.; Bustamante, J. M.; Freitas-Júnior, L. H.; Romero, L. I.; Bahia, M. T.; Lotrowska, M.; Soares, M.; Andrade, S. G.; Armstrong, T.; Degrave, W.; Andrade, Z. A. *In vitro* and *in vivo* experimental models for drug screening and development for Chagas disease. *Memórias do Instituto Oswaldo Cruz* **2010**, *105*, 233. [CrossRef] [PubMed]
- <sup>18</sup> Vazquez-Rodriguez, S.; Guíñez, R. F.; Matos, M. J.; Olea-Azar, C.; Maya, J. D. Synthesis and Trypanocidal Properties of New Coumarin-Chalcone Derivatives. *Medicinal Chemistry* **2015**, *5*, 173. [CrossRef]
- <sup>19</sup> Coelho, G. S.; Andrade, J. S.; Xavier, V. F.; Sales Júnior, P. A.; de Araujo, B. C. R.; Fonseca, K. S.; Caetano, M. S.; Murta, S. M. F.; Vieira, P. M.; Carneiro, C. M.; Taylor, J. G. Design, Synthesis, Molecular Modelling and *In Vitro* Evaluation of Tricyclic Coumarins Against *Trypanosoma Cruzi*. *Chem. Biol. Drug Des* **2019**, *93*, 337. [CrossRef] [PubMed]
- <sup>20</sup> Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews* **1997**, *23*, 3. [CrossRef]
- <sup>21</sup> Pathak, V. N.; Varshney, B.; Gupta, R. A “one pot” synthesis of 2-aryl-4H-1-benzopyran-4-ones under coupled microwave phase transfer catalysis (PTC) and ultrasonic irradiation PTC. *Journal of Heterocyclic Chemistry* **2008**, *45*, 589. [CrossRef]
- <sup>22</sup> Zhou, Z.; Zhao, P.; Huang, W.; Yang, G. A Selective Transformation of Flavanones to 3-Bromoflavones and Flavones Under Microwave Irradiation. *Advanced Synthesis & Catalysis* **2006**, *348*, 63. [CrossRef]
- <sup>23</sup> Zhu, X.; Li, Z.; Shu, Q.; Zhou, C.; Su, W. Mechanically activated solid-state synthesis of flavones by high-speed ball milling. *Synthetic Communications* **2009**, *39*, 4199. [CrossRef]
- <sup>24</sup> Theja, D. N.; Choudary T. P.; Reddy M. I.; Avsss, G.; Reddy, K. U. A facile synthesis of flavone derivatives used as potent anti-inflammatory agents. *International Journal of Pharmacy and Pharmaceutical Sciences* **2011**, *3*, 51. [Link]
- <sup>25</sup> Quintin, J.; Roullier, C.; Thoret, S.; Lewin, G. Synthesis and anti-tubulin evaluation of chromone-based analogues of combretastatins. *Tetrahedron* **2006**, *62*, 4038. [CrossRef]
- <sup>26</sup> Bapna, M.; Nema, R. k.; Development of some novel reverse transcriptase inhibitor. *Asian Journal of Chemistry* **2008**, *20*, 6022. [Link]
- <sup>27</sup> Barros, A. I. R. N. A.; Silva, A. M. S. Efficient Synthesis of Nitroflavones by Cyclodehydrogenation of 2'-Hydroxychalcones and by the Baker-Venkataraman Method. *Monatshefte für Chemie* **2006**, *137*, 1505. [CrossRef]
- <sup>28</sup> Bapna, M.; Nema, R. K. Synthesis of Some Novel Non-Nucleoside Reverse Transcriptase Inhibitor. *Asian Journal of Chemistry* **2009**, *21*, 1244. [Link]
- <sup>29</sup> Huang, X.; Tang, E.; Xu, W.-M.; Cao, J. Lewis Acid Catalyzed Solid-Phase Synthesis of Flavonoids Using Selenium-Bound Resin. *Journal of Combinatorial Chemistry* **2005**, *7*, 802. [CrossRef]
- <sup>30</sup> Thakar, K. A.; Gill, C. H. Synthesis and screening of some 1,3-propane diones and flavones. *Journal of the Indian Chemical Society* **1983**, *60*, 668.
- <sup>31</sup> Pinto, D. C. G. A.; Silva, A. M. S.; Cavaleiro, J. A. S.; Elguero, J. New Bis(chalcones) and Their Transformation into Bis(pyrazoline) and Bis(pyrazole) Derivatives. *European Journal of Organic Chemistry* **2003**, *2003*, 747. [CrossRef]
- <sup>32</sup> Bird, T. G. C.; Brown, B. R.; Stuart, I. A.; Tyrrel, A. W. R. Reactions of Flav-2-enes and Flav-2-en-4-ones (Flavones). *Journal of the Chemical Society, Perkin Transactions 1* **1983**, 1831. [CrossRef]